Cancer Pain - Pipeline Review, H1 2018
Cancer Pain - Pipeline Review, H1 2018

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk
Cancer Pain - Pipeline Review, H1 2018

Summary


Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 8, 5, 8, 1, 15, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System).

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct
Reference : GMDHC10322IDB
Number of Pages : 119
Report Format : PDF
Publisher Information :
Table Of Contents for Cancer Pain - Pipeline Review, H1 2018 [Report Updated: 10-04-2018]

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Cancer Pain - Overview
- Cancer Pain - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cancer Pain - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cancer Pain - Companies
- Cancer Pain - List of Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain -Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism
- Cancer Pain - Companies
- Cancer Pain - Products under Development by Companies
- Cancer Pain - Assessment by Target
- Cancer Pain - Assessment by Mechanism

- © BioPortfolio Limited - 2019
Market

Sep 11, 2017: Kancera announces start of Phase 1 Multiple Ascending Dose Trial of KAND567
Jul 18, 2017: Hisamitsu Pharmaceutical Announces Commence of the Phase III clinical study of HP-3150 in Japan for “cancer pain”
Jun 07, 2017: Tetra Bio-Pharma Announces the Completion of its Phase 1 Safety Report to Health Canada and Launches the Preparation of a Phase III Clinical Trial for PPP001 with Sante Cannabis
May 09, 2017: Kancera Announces Approval For The Start Of Clinical Trial Of KAND567
Apr 19, 2017: Kancera has applied for a clinical trial for KAND567
Feb 23, 2017: Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)
Feb 16, 2017: Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)
Jan 30, 2017: Tetra Bio-Pharma Completes Pre-IND Meeting with Food and Drug Administration on PPP001
Nov 02, 2016: Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board
Sep 30, 2016: Grunenthal’s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
Sep 26, 2016: PhytoPain Pharma Provides USA Regulatory Update for Its Cannabis Inhalation Product PPP001
Aug 29, 2016: Hisamitsu Pharmaceutical Announces the results of the Phase II / III clinical study of HP-3150 in Japan for “cancer pain” (an analgesic transdermal drug containing NSAIDs)
Sep 08, 2015: Kancera evaluates immuno-oncology drug candidate

Appendix

Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
How to Buy...

Cancer Pain - Pipeline Review, H1 2018 [Report Updated: 10-04-2018]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/206898

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: 
Job Title: 
Your Email: 
Your Contact Phone: 
Company Name: 
Address: 
Post/Zip Code: 
Country: 
P.O. Number: 
Any Other Instructions: 

Pricing Options: (please tick one)
○ $2000 | Single User Price
○ $4000 | Site License Price
○ $6000 | Enterprise License Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: 

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.